Molecular basis for activation and biased signaling at the thrombin-activated GPCR proteinase activated receptor-4 (PAR4).


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
21 02 2020
Historique:
received: 11 10 2019
revised: 28 12 2019
pubmed: 2 1 2020
medline: 21 10 2020
entrez: 2 1 2020
Statut: ppublish

Résumé

Proteinase-activated receptor (PAR)-4 is a member of the proteolytically-activated PAR family of G-protein-coupled receptors (GPCR) that represents an important target in the development of anti-platelet therapeutics. PARs are activated by proteolytic cleavage of their receptor N terminus by enzymes such as thrombin, trypsin, and cathepsin-G. This reveals the receptor-activating motif, termed the tethered ligand that binds intramolecularly to the receptor and triggers signaling. However, PARs are also activated by exogenous application of synthetic peptides derived from the tethered-ligand sequence. To better understand the molecular basis for PAR4-dependent signaling, we examined PAR4-signaling responses to a peptide library derived from the canonical PAR4-agonist peptide, AYPGKF-NH

Identifiants

pubmed: 31892516
pii: S0021-9258(17)48285-8
doi: 10.1074/jbc.RA119.011461
pmc: PMC7039573
pii:
doi:

Substances chimiques

Mutant Proteins 0
Peptides 0
Receptors, Thrombin 0
beta-Arrestins 0
Thrombin EC 3.4.21.5
GTP-Binding Protein alpha Subunits, Gq-G11 EC 3.6.5.1
protease-activated receptor 4 JWE1M73YZN
Alanine OF5P57N2ZX
Calcium SY7Q814VUP

Banques de données

PDB
['5NDD']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2520-2540

Subventions

Organisme : CIHR
ID : 376560
Pays : Canada

Informations de copyright

© 2020 Thibeault et al.

Références

Mol Pharmacol. 2005 May;67(5):1414-25
pubmed: 15687224
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Methods. 2016 Jan 1;92:87-93
pubmed: 26297537
Biochemistry. 2008 Dec 16;47(50):13279-86
pubmed: 19053259
Mol Pharmacol. 2017 Apr;91(4):287-295
pubmed: 28126849
J Biol Chem. 1996 Jun 14;271(24):13943-7
pubmed: 8662993
Nat Struct Mol Biol. 2018 Jan;25(1):4-12
pubmed: 29323277
J Biol Chem. 1995 Sep 15;270(37):21619-25
pubmed: 7665575
Pharmacol Ther. 2019 Aug;200:148-178
pubmed: 31075355
Methods Mol Biol. 2004;237:121-6
pubmed: 14501044
Nat Med. 2002 Oct;8(10):1161-5
pubmed: 12357249
Virology. 1973 Apr;52(2):456-67
pubmed: 4705382
Thromb Res. 2017 Jun;154:84-92
pubmed: 28448853
Am Heart J. 2009 Sep;158(3):335-341.e3
pubmed: 19699854
J Biol Chem. 2000 Dec 29;275(52):40671-8
pubmed: 11005807
Blood. 2014 Nov 27;124(23):3450-8
pubmed: 25293779
J Biol Chem. 2000 Jun 30;275(26):19728-34
pubmed: 10779527
Nat Rev Mol Cell Biol. 2002 Sep;3(9):639-50
pubmed: 12209124
J Biol Chem. 1991 Sep 15;266(26):16977-80
pubmed: 1654318
J Med Chem. 2019 Aug 22;62(16):7400-7416
pubmed: 31246024
Cell. 1991 Mar 22;64(6):1057-68
pubmed: 1672265
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
J Thromb Haemost. 2005 Aug;3(8):1800-14
pubmed: 16102047
Sci Transl Med. 2017 Jan 4;9(371):
pubmed: 28053157
J Biol Chem. 2011 Feb 4;286(5):3805-14
pubmed: 21106537
Lancet. 2012 Oct 13;380(9850):1317-24
pubmed: 22932716
Mol Pharmacol. 2018 Apr;93(4):251-258
pubmed: 29298813
J Med Chem. 2011 Mar 10;54(5):1308-13
pubmed: 21294569
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W665-7
pubmed: 15215472
J Cardiovasc Pharmacol. 2017 Sep;70(3):142-158
pubmed: 28328745
Nature. 1998 Aug 13;394(6694):690-4
pubmed: 9716134
Methods Cell Biol. 2016;132:341-58
pubmed: 26928551
Biochem J. 2003 Dec 15;376(Pt 3):733-40
pubmed: 13678420
Nature. 1994 Apr 14;368(6472):648-51
pubmed: 8145852
Br J Pharmacol. 2016 Oct;173(20):2952-65
pubmed: 26844674
Biochemistry. 2007 Jul 24;46(29):8603-10
pubmed: 17595115
Nat Biotechnol. 2013 Sep;31(9):827-32
pubmed: 23873081
Br J Pharmacol. 1999 Nov;128(5):1105-13
pubmed: 10556949
Nature. 2013 Feb 14;494(7436):185-94
pubmed: 23407534
Br J Pharmacol. 2000 Jul;130(6):1289-96
pubmed: 10903968
J Biol Chem. 2006 Sep 8;281(36):26665-74
pubmed: 16837456
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11023-7
pubmed: 10500117
J Biol Chem. 1996 Jul 12;271(28):16466-71
pubmed: 8663335
Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456
pubmed: 29269513
Annu Rev Biophys. 2018 Mar 2;:
pubmed: 29498889
Br J Pharmacol. 2010 May;160(2):191-203
pubmed: 20423334
Nature. 2017 May 4;545(7652):112-115
pubmed: 28445455
J Biol Chem. 2000 Aug 18;275(33):25216-21
pubmed: 10837487
Br J Pharmacol. 2014 Mar;171(5):1180-94
pubmed: 24354792
Circulation. 2006 Mar 7;113(9):1244-54
pubmed: 16505172
Angew Chem Int Ed Engl. 2019 Jun 11;58(24):8216-8220
pubmed: 30958917
Int J Mol Sci. 2018 Feb 14;19(2):
pubmed: 29443899
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9208-12
pubmed: 7937743
J Biol Chem. 2004 Nov 12;279(46):47438-45
pubmed: 15339913
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
Mol Cell Endocrinol. 2017 Jul 5;449:3-11
pubmed: 27899324
Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1632-1643
pubmed: 29748334
Br J Pharmacol. 2012 Mar;165(6):1688-1703
pubmed: 21864311
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6642-6
pubmed: 9618465
N Engl J Med. 2012 Apr 12;366(15):1404-13
pubmed: 22443427
J Pharmacol Exp Ther. 2002 Sep;302(3):1046-54
pubmed: 12183662
Platelets. 2017 Dec;28(8):812-821
pubmed: 28267389
Nucleic Acids Res. 2015 Jul 1;43(W1):W431-5
pubmed: 25969449
Pharmacol Ther. 2011 Jun;130(3):248-82
pubmed: 21277892
Mol Pharmacol. 2014 Jul;86(1):1-11
pubmed: 24723492
J Biol Chem. 1992 Jul 5;267(19):13146-9
pubmed: 1320011
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Nature. 1997 Apr 3;386(6624):502-6
pubmed: 9087410

Auteurs

Pierre E Thibeault (PE)

Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A5C1, Canada.

Jordan C LeSarge (JC)

Department of Chemistry, University of Western Ontario, London, Ontario N6A5C1, Canada.

D'Arcy Arends (D)

Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A5C1, Canada.

Michaela Fernandes (M)

Department of Chemistry, University of Western Ontario, London, Ontario N6A5C1, Canada.

Peter Chidiac (P)

Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A5C1, Canada.

Peter B Stathopulos (PB)

Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A5C1, Canada.

Leonard G Luyt (LG)

Department of Chemistry, University of Western Ontario, London, Ontario N6A5C1, Canada; Department of Oncology, University of Western Ontario, London, Ontario N6A5C1, Canada; London Regional Cancer Program, Lawson Health Research Institute, London, Ontario N6C2R5, Canada.

Rithwik Ramachandran (R)

Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A5C1, Canada. Electronic address: rramach@uwo.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH